Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA 9,500.00
-80.00 (-0.84%)
Jul 27, 2026, 5:29 PM IDT
TLV:TEVA Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17,349 | 17,258 | 16,544 | 15,846 | 14,925 | 15,878 | |
Revenue Growth | 4.41% | 4.32% | 4.41% | 6.17% | -6.00% | -4.69% |
Cost of Revenue | 8,317 | 8,320 | 8,481 | 8,200 | 7,952 | 8,284 |
Gross Profit | 9,032 | 8,938 | 8,063 | 7,646 | 6,973 | 7,594 |
Selling, General & Admin | 4,054 | 3,973 | 3,702 | 3,498 | 3,445 | 3,528 |
Research & Development | 988 | 1,013 | 998 | 953 | 838 | 967 |
Other Operating Expenses | -16 | - | -10 | 10 | 28 | 20 |
Operating Expenses | 5,026 | 4,986 | 4,690 | 4,461 | 4,311 | 4,515 |
Operating Income | 4,006 | 3,952 | 3,373 | 3,185 | 2,662 | 3,079 |
Interest Expense | -895 | -916 | -1,002 | -1,029 | -930 | -891 |
Interest & Investment Income | 92 | 92 | 86 | 68 | 10 | - |
Earnings From Equity Investments | 14 | 15 | 1 | 2 | 21 | 9 |
Currency Exchange Gain (Loss) | 10 | -41 | -17 | -30 | 16 | -7 |
Other Non Operating Income (Expenses) | -131 | -71 | -48 | -66 | -62 | -69 |
EBT Excluding Unusual Items | 3,096 | 3,031 | 2,393 | 2,130 | 1,717 | 2,121 |
Merger & Restructuring Charges | -236 | -225 | -74 | -111 | -146 | -133 |
Impairment of Goodwill | - | - | -1,280 | -700 | -2,045 | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -90 |
Gain (Loss) on Sale of Assets | -20 | -20 | 17 | 28 | 64 | 58 |
Asset Writedown | -960 | -1,028 | -1,275 | -378 | -402 | -584 |
Legal Settlements | -453 | -467 | -761 | -1,043 | -2,069 | -698 |
Other Unusual Items | -48 | -54 | -303 | -548 | -261 | -7 |
Pretax Income | 1,379 | 1,237 | -1,283 | -622 | -3,142 | 667 |
Income Tax Expense | -187 | -180 | 676 | -7 | -643 | 211 |
Earnings From Continuing Operations | 1,566 | 1,417 | -1,959 | -615 | -2,499 | 456 |
Minority Interest in Earnings | -1 | -7 | 320 | 56 | 53 | -39 |
Net Income | 1,565 | 1,410 | -1,639 | -559 | -2,446 | 417 |
Net Income to Common | 1,565 | 1,410 | -1,639 | -559 | -2,446 | 417 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,150 | 1,145 | 1,131 | 1,119 | 1,110 | 1,102 |
Shares Outstanding (Diluted) | 1,168 | 1,163 | 1,131 | 1,119 | 1,110 | 1,107 |
Shares Change | 2.93% | 2.83% | 1.07% | 0.81% | 0.27% | 1.10% |
EPS (Basic) | 1.36 | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 |
EPS (Diluted) | 1.34 | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,172 | 1,148 | 749 | 842 | 1,042 | 236 |
Free Cash Flow Per Share | 1.00 | 0.99 | 0.66 | 0.75 | 0.94 | 0.21 |
Gross Margin | 52.06% | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% |
Operating Margin | 23.09% | 22.90% | 20.39% | 20.10% | 17.84% | 19.39% |
Profit Margin | 9.02% | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% |
Free Cash Flow Margin | 6.75% | 6.65% | 4.53% | 5.31% | 6.98% | 1.49% |
EBITDA | 5,003 | 4,954 | 4,432 | 4,338 | 3,970 | 4,409 |
EBITDA Margin | 28.84% | 28.71% | 26.79% | 27.38% | 26.60% | 27.77% |
D&A For EBITDA | 997 | 1,002 | 1,059 | 1,153 | 1,308 | 1,330 |
EBIT | 4,006 | 3,952 | 3,373 | 3,185 | 2,662 | 3,079 |
EBIT Margin | 23.09% | 22.90% | 20.39% | 20.10% | 17.84% | 19.39% |
Effective Tax Rate | - | - | - | - | - | 31.63% |
Advertising Expenses | - | - | - | - | - | 246 |